The third edition of this book, published in February 2016, included 29 antiseizure medications (ASMs). Since then, four new ASMs have been licensed for clinical use (cannabidiol, cenobamate, everolimus, and fenfluramine), and one ASM (retigabine) is no longer licensed for clinical use. Consequently, there has been a surge of publications reporting on interactions, particularly interactions involving the newer ASMs. In this fourth edition, a total of 32 ASMs are reviewed, in alphabetical order, including ASMs that are not necessarily licensed worldwide but that are prescribed to patients in different countries (e.g., acetazolamide, methsuximide, piracetam, and sulthiame).
نظرات کاربران